Skip to content

EBITDA at other companies

NeoGenomics logo
NeoGenomicsNEO
-$1.83M+81.9%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$29.79M-97.2%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Labcorp Holdings logo
Labcorp HoldingsLH
Quest Diagnostics logo
Quest DiagnosticsDGX
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Revenue$71.1M-3.2%
Gross profit$21.5M-24.2%
Operating income-$34.6M-74.9%
Net income-$24.8M-115%
EPS (diluted)-$0.80-116%

Balance sheet

See full
Cash & equivalents$23.4M-65.2%
Total debt$8.2M+40.5%
Total equity$1.0B-6.9%
Total assets$1.2B-4.1%

Cash flow

See full
Operating cash flow$7.1M+260%
CapEx$5.2M+10.3%
Free cash flow$1.9M+121%

Valuation

See full
Market cap$552.11M-7.1%
Enterprise value$536.92M+0.7%
P/S1.7×-0.3×

Profitability

See full
Gross margin38.7%-0.1pp
Operating margin-33.1%+17.4pp
Net margin-23%+43.3pp
FCF margin-36.9%

Returns & leverage

See full
Return on equity-6.8%+48.2pp
Debt / equity0.0×
Current ratio5.3×-1.0×

Where this comes from

Calculated from Fulgent Genetics, Inc.’s reported figures.

$34.6Mebit+
$6.0MDepreciation Depletion & Amortization
=-$28.62M

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s EBITDA?
Fulgent Genetics, Inc. (FLGT) reported EBITDA of -$28.62M in Q1 2026.
How has Fulgent Genetics, Inc.'s EBITDA changed year-over-year?
Fulgent Genetics, Inc.'s EBITDA decreased by 106.3% year-over-year, from -$13.88M to -$28.62M.
What is the long-term trend for Fulgent Genetics, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Fulgent Genetics, Inc.'s EBITDA has grown at a -44.1% compound annual growth rate (CAGR), from $686.96M to -$66.97M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.